Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary endpoint of a statistically significant increase in salivary flow production compared to placebo at all three doses: 10 mg, 15 mg, and 20 mg. These doses were safe and well tolerated with few reports of excessive sweating and gastrointestinal complaints.

"The preliminary data look very impressive and offer new hope to patients with Sjogren's syndrome," said principal investigator Frederick B. Vivino, M.D., Chief, Division of Rheumatology, Penn Presbyterian Medical Center, Clinical Associate Professor of Medicine, University of Pennsylvania School of Medicine and Director of the Penn Sjogren's Syndrome Center. "NGX267 appears to be efficacious, safe and well tolerated in short term use. The results of this recently completed clinical trial undoubtedly justify the design and execution of longer placebo-controlled trials in a larger group of Sjogren's syndrome patients. This will help us better elucidate the full benefit of this novel treatment."

"The findings from this study are very promising given the demonstrated efficacy and low incidence of adverse events for the three doses of NGX267," said Ev Graham, Chief Executive Officer of TorreyPines. "Moving forward, we now have data that suggests this well-tolerated product candidate could be effective in treating dry mouth associated with Sjogren's syndrome, and possibly other conditions in which a reduction in salivary flow has been observed such as the effects of head and neck radiation, diabetes and aging. According to our preliminary market research, there is a significant need f
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 The Physician-Patient Alliance for Health ... 28, 2015, "Surviving Your Hospital Stay: Physician-Patient Alliance ... Safety." A sentence was omitted from ... "PPAHS is a member of the National Coalition ... information on the National Coalition to Promote Continuous Monitoring ...
(Date:7/31/2015)... According to a new market research ... Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), ... Global Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment ... 2020, at a CAGR of 7.6%.from 2015 to 2020. ... T ables and 37 F ...
(Date:7/31/2015)... 31, 2015 Quietly, sedately, Morocco,s ... the domestic pharmaceutical industry is strong, with a well-developed ... high international standards. One place where the ... sub-Saharan Africa: Morocco has quietly become the second largest ... Africa . Indeed, Moroccan pharma companies have been ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... MYL ) today announced that its business Mylan Institutional ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... Single-use Vials. This product is the generic version of Pharmacia ... Dexrazoxane for Injection, when indicated for the same ...
... has added new capabilities in CNC Screw Machining to ... device industry. In addition to its well-established capabilities in ... offers precision CNC machining of small custom components for ... machining equipment is capable of a variety of operations, ...
Cached Medicine Technology:Pulse Systems Announces Addition of CNC Machining Services 2
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... new industry players to know in predictive health analytics , Jvion continues ... technologies. The firm creates predictive software that targets patient and population level illness ...
(Date:7/31/2015)... ... 2015 , ... The 2nd annual Ride to Fight On will start and ... 2015. The Ride to Fight On is a cycling fundraiser that benefits the West ... Clinic and The University of Tennessee Health Science Center. A health and wellness festival ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way ... when it comes time to cook the next meal, making July the most appropriate ... practicing best grilling tips and recipes. , Make the next cookout different than the ...
(Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
(Date:7/31/2015)... ... ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep in ... The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection of ... easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific content ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... Davos: The Hinduja Group is making a $1 billion ... in several cities and a modern research centre,// a ... ,‘We already have a charitable hospital in Mumbai. This ... like Ahmedabad, Bangalore, Chennai, Hyderabad and Pune,’ Prakash P. ...
... in the last ten years, and only the third, after ... smoking cessation. ,The new anti-smoking drug varenicline ... December 2006. An early Cochrane Review' of its effectiveness shows ... of a person quitting smoking. ,People become ...
... that Multidetector CT (MDCT) without the use of contrast media can ... in avoiding the need for surgeons to do exploratory surgery of ... ,In the past, the best way to find a perforation in ... watch to see if and where the contrast media leaked from ...
... aged 40 and older are getting mammography done nowadays.// ... deaths down the line, according to concerned experts. ... are disturbed about this decline. ,"Maybe women need ... been around for a long time, it's still the best ...
... have suggested that drinking a lot of coffee during pregnancy ... miscarriage or premature delivery. ,A recent research by ... link between caffeine intake and pregnancy outcome. ... in the initial stages of pregnancy who drank three cups ...
... study finds that the children who lived close to main ... findings were published online by 'The Lancet' medical journal.// ... people, from age of 10-18, growing up near the roadways ... to their lungs from exhaust fumes. Traffic pollution prevents the ...
Cached Medicine News:Health News:Mammography Saves Life-Beware Women Over 40 2
... With BareWire technology, the wire crosses the ... delivery catheter. All other actions, including filter ... placement then occur over the wire., ,Emboshield ... break off during a carotid stenting procedure, ...
... Designed to fully integrate ... multidisciplinary clinical laboratory working under ... suite uses five core modules ... management and create an environment ...
... Fully automated chemiluminescence assay ... growth hormone in serum. Growth ... hormone secreted by the anterior ... of hypothalamic growth hormone releasing ...
... unique DHEA-S-7kits feature a ... against the C-7 position ... with no cross-reactivity with ... RIA has been optimized ...
Medicine Products: